Jabez Biosciences

Jabez Biosciences is a clinical-stage biopharmaceutical company in Cranberry Township, Pennsylvania developing small-molecule cancer therapies for liquid and solid tumors. Its lead candidate, JBZ-001, is an oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine nucleotide synthesis pathway, and is in a Phase 1 study in advanced solid tumors and non-Hodgkin lymphoma. The company in-licenses and develops assets translated from academic cancer research rather than running its own discovery platform. A separate NCI-funded Phase 1 trial of JBZ-001 in acute myeloid leukemia is being opened with the University of Cincinnati Cancer Center and The Ohio State University Comprehensive Cancer Center under a grant of more than $3.4 million.

A '3-S' selection filter — Seamless (oral, low-toxicity, outpatient-compatible), Scalable (cost-effective manufacturing chemistry), and Synergistic (mechanistically compatible with standard-of-care regimens) — applied to in-licensed academic assets to shorten development timelines and cost versus building a discovery platform in-house.